By Tarun Sai LomteMar 18 2024Reviewed by Lily Ramsey, LLM In a recent study published in npj Parkinson’s disease, researchers evaluated the differences in the progression of Parkinson’s disease between real-world and research populations.
Moreover, different patterns of PD progression and diverse onset ages suggest heterogeneity. Recent studies have uncovered at least six loci associated with genetic heterogeneity in PD progression to Lewy body dementia. PD progression was evaluated using common clinical rating scales, including the mini-mental-state examination , Montreal cognitive assessment , unified PD rating scale , and Hoehn and Yahr .
Further, in RWD sources, individuals were excluded if they developed conditions leading to clinical parkinsonism symptoms during the quiescence period. The average follow-up period was 6.1 years in HBS compared to 3.2 years in real-world populations. In general, clinical scores showed smaller changes over time in HBS compared to MGB. Optum lacked clinical rating scores.